Hotgen: The patent for the target of small nucleic acid therapeutic drugs for Alzheimer's disease held by its invested company has been authorized
According to Hotgen, recently, a patent for "siRNA and its conjugates that inhibit APP gene expression and their applications" held by Beijing Yaojing Gene Technology Co., Ltd., in which Hotgen has a stake, has officially been authorized. This patent is for a small nucleic acid drug aimed at the treatment of Alzheimer's disease